SGX Mainboard-listed CDW Holding Limited has unveiled pre-clinical results for a new drug delivery platform that management believes could become a future growth engine for the group. Through its life sciences subsidiary A Biotech Co., Limited (ABio) and partner Neoregen Biotech, CDW is developing LNP-LANFA, a next-generation lipid nanoparticle technology aimed at delivering nucleic acid therapeutics and mRNA vaccines more safely and effectively.
LNP-LANFA incorporates LANFA, CDW’s proprietary water-soluble compound designed as a biocompatible and biodegradable alternative to widely used polyethylene glycol (PEG). LANFA, patented in Japan in December 2025 with an international application filed under the Patent Cooperation Treaty, is engineered to improve solubility and formulation of drugs and nanomedicines in aqueous systems.
Animal studies show improved targeting and low immunogenicity
In animal studies conducted by WOOJUNG BIO, a South Korean non-clinical contract research organisation holding full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International), LNP-LANFA showed markedly different behaviour from conventional LNPs. Imaging tests indicated a 62% reduction in liver accumulation and a 28% increase in delivery to the spleen, improving the spleen-to-liver ratio from 0.79 to 2.68, a 3.4-fold gain.
CDW says better targeting of the spleen, the body’s immune “command centre”, could be important for vaccines, cancer immunotherapies and other immune-related treatments. At the BIO International Convention in San Diego, ABio and Neoregen also presented the latest pre-clinical in vivo data from murine studies, showing a 3.3-fold improvement in the spleen-to-liver distribution ratio.
The company is also positioning LNP-LANFA as a potential answer to safety questions that have emerged around PEG-containing formulations. In immunogenicity tests carried out by Kobe Gakuin University, LANFA alone produced antibody levels associated with rejection reactions that were no higher than saline in mice, suggesting low immunogenicity and potential suitability for repeated dosing, subject to further work.
Early-stage discussions
ABio conducted 37 business meetings at the convention with pharmaceutical companies, biotechnology companies and research organisations, and will continue technical follow-up discussions with a view to potential licensing and development collaborations. No definitive licensing agreements have been entered into. LNP-LANFA remains at the pre-clinical stage, and further non-clinical studies, regulatory review and clinical development will be required before any commercial application.
